In the Nathanson dataset, melanoma patients with low TIIC signature scores showed better survival outcomes (Figure 7L), and melanoma patients with low TIIC signature scores presented better responses to anti‐CTLA‐4 immunotherapy (Figure 7M). Here, CTLA4 is linked to melanoma.